Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

OCGN

Ocugen Inc

May 15 • 03:03PM ET

1.96

Dollar change +0.25
Percentage change 15.00	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF VHT ITOT GERM AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.24	Insider Own	2.20%	Shs Outstand	256.57M	Perf Week	13.66%
Market Cap	503.08M	Forward P/E	-	EPS next Y	-0.28	Insider Trans	0.00%	Shs Float	251.68M	Perf Month	22.96%
Income	-59.98M	PEG	-	EPS next Q	-0.06	Inst Own	11.11%	Short Float	19.03%	Perf Quarter	193.10%
Sales	2.42M	P/S	207.88	EPS this Y	3.85%	Inst Trans	-2.90%	Short Ratio	4.58	Perf Half Y	435.62%
Book/sh	0.12	P/B	16.63	EPS next Y	-12.00%	ROA	-81.00%	Short Interest	47.89M	Perf Year	166.35%
Cash/sh	0.10	P/C	19.07	EPS next 5Y	-	ROE	-113.11%	52W Range	0.34 - 2.11	Perf YTD	240.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	41.20%	ROI	-170.36%	52W High	-7.13%	Beta	3.58
Dividend TTM	-	Quick Ratio	1.87	Sales past 5Y	8.52%	Gross Margin	65.21%	52W Low	466.67%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	1.87	EPS Y/Y TTM	29.42%	Oper. Margin	-4856.85%	RSI (14)	64.92	Volatility	10.97% 11.95%
Employees	65	Debt/Eq	0.23	Sales Y/Y TTM	-	Profit Margin	-2475.48%	Recom	1.00	Target Price	6.67
Option/Short	Yes / Yes	LT Debt/Eq	0.16	EPS Q/Q	36.61%	Payout	-	Rel Volume	1.44	Prev Close	1.70
Sales Surprise	-	EPS Surprise	21.01%	Sales Q/Q	-	Earnings	May 14 BMO	Avg Volume	10.46M	Price	1.96
SMA20	36.47%	SMA50	38.63%	SMA200	169.93%	Trades		Volume	12,992,445	Change	15.00%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-01-23	Upgrade	Chardan Capital Markets	Neutral → Buy	$3.50
Aug-23-22	Initiated	Mizuho	Buy	$5
Jun-15-22	Resumed	ROTH Capital	Buy	$8
Jun-02-22	Initiated	Cantor Fitzgerald	Overweight	$4.50
Jul-26-21	Initiated	Noble Capital Markets	Outperform
Jun-11-21	Downgrade	ROTH Capital	Buy → Neutral	$10 → $6
May-07-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-09-21	Downgrade	Chardan Capital Markets	Buy → Neutral	$0.70 → $13
Feb-04-21	Upgrade	H.C. Wainwright	Neutral → Buy	$4.50

Today 07:30AM	Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study (MT Newswires) +15.00%
06:30AM	Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST A Modifier Gene Therapy (GlobeNewswire)
03:02AM	Ocugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances Amid ... (GuruFocus.com)
01:12AM	Q1 2024 Ocugen Inc Earnings Call (Thomson Reuters StreetEvents)
May-14-24 11:53AM	OCGN Stock Earnings: Ocugen Beats EPS for Q1 2024 (InvestorPlace) -6.08%
08:00AM	Loading…
08:00AM	Ocugen Provides Business Update with First Quarter 2024 Financial Results (GlobeNewswire)
06:43AM	Ocugen: Q1 Earnings Snapshot (Associated Press Finance)
May-10-24 04:05PM	Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock (GlobeNewswire)
07:45AM	Ocugen to Present at May 2024 Investor Conferences (GlobeNewswire)
May-08-24 06:00AM	Millionaire Blueprint: 3 Stocks Under $5 With Massive Growth Potential by 2028 (InvestorPlace) +9.55%
May-03-24 07:30AM	Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results (GlobeNewswire)
May-02-24 07:15AM	Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress (GlobeNewswire) -5.04%
Apr-29-24 08:30AM	Can Ocugen Stock Keep Churning Higher? (Motley Fool) +8.59%
06:45AM	Ocugen Announces OCU400 Modifier Gene Therapy Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 (GlobeNewswire)
Apr-28-24 11:59AM	5 ChatGPT Penny Stock Picks Right Now (Insider Monkey)
12:35PM	Loading…
Apr-26-24 12:35PM	Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards? (Zacks) +8.47%
09:05AM	UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting (GlobeNewswire)
06:30AM	Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting (GlobeNewswire)
Apr-19-24 07:13AM	Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410-A Modifier Gene Therapy (GlobeNewswire)
Apr-16-24 10:53PM	OCGN Stock Earnings: Ocugen Beats EPS for Q4 2023 (InvestorPlace)
Apr-12-24 07:30AM	Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets (GlobeNewswire)
Apr-10-24 07:02AM	Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400 Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication (GlobeNewswire) +5.26%
Apr-08-24 12:13PM	Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study (Zacks)
10:57AM	Why Is Ocugen (OCGN) Stock Up 7% Today? (InvestorPlace)
06:30AM	Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication (GlobeNewswire)
Apr-05-24 03:30PM	OCGN Stock Alert: Why Is Ocugen Up 20% Today? (InvestorPlace) +21.19%
07:02AM	Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410 a Modifier Gene Therapy in Phase 1/2 ArMaDa Study for Geographic Atrophy (GlobeNewswire)
Apr-02-24 10:50PM	Q4 2023 Ocugen Inc Earnings Call (Thomson Reuters StreetEvents) -10.39%
07:00PM	Ocugen (OCGN) Q4 2023 Earnings Call Transcript (Motley Fool)
03:15PM	OCGN Stock Falls Ocugen Must Restate Its Financials (InvestorPlace)
08:00AM	Loading…
08:00AM	Ocugen Provides Business Update with Certain Financials for the Year Ending 2023 (GlobeNewswire)
Apr-01-24 06:08PM	Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST a Modifier Gene Therapy in GARDian Study for Stargardt Disease (GlobeNewswire) -6.10%
05:43PM	Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023 (GlobeNewswire)
Mar-25-24 11:58AM	Why Is Ocugen (OCGN) Stock Up 20% Today? (InvestorPlace) +11.59%
07:32AM	3 Stocks Under $5 Ready to Outpace the Market (InvestorPlace)
Mar-18-24 06:30AM	Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer (GlobeNewswire)
Mar-13-24 08:00AM	Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 (GlobeNewswire) +5.69%
Mar-07-24 05:28AM	Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street (Motley Fool) +16.09%
Mar-06-24 07:30AM	Ocugen to Present at Investing in Cures Summit (GlobeNewswire)
Feb-28-24 08:00AM	Ocugen Clinical Showcase Webcast Now Available (GlobeNewswire)
Feb-26-24 04:34PM	Meme Stock Meltdowns: 3 Names to Sell Before They Crash (InvestorPlace) +13.28%
08:30AM	Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit (GlobeNewswire)
Feb-22-24 04:05PM	Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST (GlobeNewswire) -5.98%
12:56PM	5 Hot Penny Stock On the Move (Insider Monkey)
Feb-21-24 04:05PM	Ocugen to Present at 2024 BIO CEO & Investor Conference (GlobeNewswire)
Feb-20-24 10:26AM	Dear OCGN Stock Fans, Mark Your Calendars for Feb. 21 (InvestorPlace) +9.58%
Feb-14-24 07:30AM	Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024 (GlobeNewswire) +9.34%
Jan-31-24 08:00AM	Ocugen to Present at Pharma Market Research Conference (GlobeNewswire)
Jan-16-24 07:30AM	Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board (GlobeNewswire) -6.43%
Dec-21-23 06:30AM	Ocugen Gains FDA Alignment on Key Aspects of OCU400 Modifier Gene Therapy Pivotal Phase 3 Study Design (GlobeNewswire) +6.86%
Dec-19-23 07:30AM	Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations (GlobeNewswire) +5.83%
Dec-13-23 07:30AM	Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (GlobeNewswire)
Nov-29-23 07:30AM	Ocugen CEO to Present at NobleCon19 Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference (GlobeNewswire)
Nov-10-23 01:54PM	Ocugen, Inc. (NASDAQ:OCGN) Q3 2023 Earnings Call Transcript (Insider Monkey)
07:30AM	Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST Modifier Gene Therapy for Stargardt Disease (GlobeNewswire)
02:07AM	Q3 2023 Ocugen Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 11:45AM	Ocugen (OCGN) Q3 2023 Earnings Call Transcript (Motley Fool)
08:38AM	Ocugen Inc (OCGN) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
07:00AM	Ocugen: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Ocugen Provides Business Update with Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-07-23 07:45AM	Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit (GlobeNewswire)
Nov-02-23 07:30AM	Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-10-23 09:58AM	Why Is Ocugen (OCGN) Stock Up 5% Today? (InvestorPlace) +10.27%
06:30AM	Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials (GlobeNewswire)
Oct-04-23 07:00AM	Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa (GlobeNewswire)
Sep-29-23 07:30AM	Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference (GlobeNewswire)
Sep-27-23 07:30PM	Ocugen to Participate in Fireside Chat at Chardan s 7th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-21-23 07:30AM	Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board (GlobeNewswire)
Sep-20-23 08:00AM	Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023 (GlobeNewswire)
Sep-13-23 08:15AM	Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) (GlobeNewswire)
Sep-12-23 07:30PM	Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023 (GlobeNewswire)
Aug-24-23 09:48AM	Ocugen, Inc. (NASDAQ:OCGN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-23-23 02:05AM	Q2 2023 Ocugen Inc Earnings Call (Thomson Reuters StreetEvents) +16.84%
Aug-22-23 12:00PM	Ocugen (OCGN) Q2 2023 Earnings Call Transcript (Motley Fool) -8.96%
Aug-21-23 04:32PM	Ocugen Provides Business Update with Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-18-23 04:39PM	Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-25-23 08:58PM	3 Millionaire-Maker Growth Stocks to Buy Before the Window (InvestorPlace)
Jul-13-23 07:00AM	7 Biotech Stocks to Sell in July (InvestorPlace)
Jun-30-23 08:00AM	Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly (GlobeNewswire)
Jun-09-23 04:05PM	Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders (GlobeNewswire)
Jun-05-23 07:02AM	Ocugen, Inc. Announces Business Advisory Board (GlobeNewswire)
May-25-23 02:00PM	Wall Street Expects These Stocks to Soar 175% and 545%. Should You Buy? (Motley Fool)
May-24-23 08:36AM	Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock (GlobeNewswire) -35.05%
May-23-23 04:01PM	Ocugen, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
08:00AM	Ocugen to Present at BIO International Convention 2023 (GlobeNewswire)
May-05-23 03:00PM	Ocugen (OCGN) Q1 2023 Earnings Call Transcript (Motley Fool)
07:17AM	Ocugen: Q1 Earnings Snapshot (AP Finance)
07:00AM	Ocugen Provides Business Update with First Quarter 2023 Financial Results (GlobeNewswire)
Apr-28-23 07:00AM	Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results (GlobeNewswire)
Apr-27-23 07:25AM	Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies (GlobeNewswire)
Apr-26-23 06:30AM	Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
Apr-20-23 08:00AM	Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting (GlobeNewswire) -5.79%
Apr-14-23 01:47PM	Ocugen Highlights Interim Data From Gene Therapy Study For Genetic Vision Loss Disorder (Benzinga) -5.97%
07:45AM	Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis (GlobeNewswire)
Apr-11-23 06:20PM	Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023 (GlobeNewswire) +7.37%
Mar-31-23 08:15AM	Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress (GlobeNewswire)
Mar-27-23 08:00AM	Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) (GlobeNewswire)
Mar-07-23 08:00AM	Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference (GlobeNewswire)
Mar-06-23 07:02AM	Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer (GlobeNewswire) -5.49%
Mar-02-23 07:02AM	Ocugen, Inc. (NASDAQ:OCGN) Q4 2022 Earnings Call Transcript (Insider Monkey)

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zhang Junge	Director	Jun 14 '23	Buy	0.50	200,278	99,999	1,077,182	Jun 16 04:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OCGN

Ocugen Inc

Upgrade your FINVIZ experience